Niagen Bioscience (NAGE) Receivables - Net (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Receivables - Net of $13.1 million for Q1 2026, up 84.51% year-over-year from $7.1 million in Q1 2025, and up 34.48% quarter-over-quarter from $9.7 million in Q4 2025.
Niagen Bioscience (NAGE) Receivables - Net (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Receivables - Net for 16 consecutive years, with $13.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 84.51% year-over-year to $13.1 million; the TTM figure through Mar 2026 stood at $13.1 million (up 84.51% YoY), while the FY2025 annual figure was $9.7 million, up 25.4% from the prior year.
- Receivables - Net improved to $13.1 million in Q1 2026 per NAGE's latest filing, from $9.7 million in the prior quarter.
- Across five years, Receivables - Net topped out at $13.1 million in Q1 2026 and bottomed at $2.8 million in Q2 2023.
- Historically, Receivables - Net has averaged $6.8 million across 5 years, with a median of $7.1 million in 2024.
- Annual changes were most pronounced in 2022 — Receivables - Net plunged 40.68% — and 2024, when it surged 179.21%.
- Niagen Bioscience's Receivables - Net stood at $3.1 million in 2022, then jumped by 68.84% to $5.2 million in 2023, then soared by 48.41% to $7.8 million in 2024, then climbed by 25.4% to $9.7 million in 2025, then soared by 34.48% to $13.1 million in 2026.
- Business Quant data shows NAGE's Receivables - Net at $13.1 million in Q1 2026, $9.7 million in Q4 2025, and $8.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.60 Mn |
| Jun 30, 2026 | 8.60 Mn |
| Mar 31, 2026 | 13.10 Mn |
| Mar 31, 2026 | 13.10 Mn |
| Dec 31, 2025 | 9.74 Mn |
| Dec 31, 2025 | 9.74 Mn |
| Sep 30, 2025 | 8.51 Mn |
| Sep 30, 2025 | 8.51 Mn |
| Jun 30, 2025 | 9.70 Mn |
| Jun 30, 2025 | 9.70 Mn |
| Mar 31, 2025 | 7.10 Mn |
| Mar 31, 2025 | 7.10 Mn |
| Dec 31, 2024 | 7.77 Mn |
| Dec 31, 2024 | 7.77 Mn |
| Sep 30, 2024 | 7.10 Mn |
| Sep 30, 2024 | 7.10 Mn |
| Jun 30, 2024 | 7.82 Mn |
| Jun 30, 2024 | 7.82 Mn |
| Mar 31, 2024 | 6.60 Mn |
| Mar 31, 2024 | 6.60 Mn |